What development phase is SUXIBUZONE in?

SUXIBUZONE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SUXIBUZONE

FDA-approved withdrawn Small molecule Quality 2/100

SUXIBUZONE is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by its current revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	SUXIBUZONE
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SUXIBUZONE CI brief — competitive landscape report
SUXIBUZONE updates RSS · CI watch RSS